Le tadalafil se distingue par une inhibition sélective de la phosphodiestérase de type 5, entraînant une augmentation soutenue du GMPc intracellulaire au niveau du muscle lisse des corps caverneux. Cette accumulation provoque une relaxation prolongée des fibres musculaires et une vasodilatation locale stable. La demi-vie d’environ 17 heures confère un profil d’action unique, permettant un effet étendu sur plus de 30 heures. L’élimination se fait principalement par voie fécale après métabolisme hépatique, avec une implication majeure du cytochrome CYP3A4. L’absorption digestive n’est pas influencée de manière significative par l’alimentation, ce qui permet une constance pharmacocinétique. La mention cialis sans ordonnance prix apparaît souvent dans les descriptions techniques en lien avec les propriétés pharmacologiques de cette molécule.

Helenmitchell.com

USMEDSA Urology Coordinating Team 2000 Accomplishments vs Objectives
OBJECTIVES
ACCOMPLISHMENTS
Coordinate Merck Activities & Exhibits at Medical Meetings • Very successful exhibit presence at AUA 2000 Annual Meeting, Pri-Med, AACE & AAFP meetings • Sponsored BPH Week as part of AFUD’s 2nd Annual Prostate
DUCATE PHYSICIANS
Health Month • AUA Annual meeting: hosted Merck Advocate Event (450 Uro’s), sponsored- AUA CME BPH Symposia (650 Uro’s), AUA Education Store, AUA CD ROM of Course Handouts (6000 MD’s), AUA Website, Abstracts Online, &
Annual Meeting Planner • Provided the Audience Response System for the AUA Board Review Courses • Supported the: AUA Long Range Strategic Planning, AUA Chiefs of Urol Program, AUA/EAU Exchange Program
ABOUT DATA FOR PROSCAR
Provide Medical & Scientific Information • Conducted 3 Regional CME Programs, “Advances in the Eval. & Pharmacologic 3)3
Tx of BPH”. Monograph published & will be posted on Medscape for CME credit for 1 yr • Developed
AND ASSIST IN THE LAUNCH OF
exhibits for AUA 2000 Annual Meeting (& sponsored CD ROM), Pri-Med Meetings, AACE & AAFP meetings. • Sponsored AUA CME program that is being evaluated by Audio Digest for inclusion in its tape program. • Worked with Annenberg
Center for Health Sciences to create a Journal Plus Program (CME) on “The Role of Serum PSA in BPH” • Database updated with all product AUA abstracts, HCP’s product & disease questions answered in writing &/or by personal calls.
• *Ongoing participation in MRL manuscript review/revision process, & Medical School Grant Committee • *Prostatitis & Hematuria MSGP’s- Assisted US investigators with investigator-IND application, provided investigators with double-blind
THE PSA LABEL CHANGES
medication via outside vendor • * Participated in WPCRC activities related to the cir
cular additions on the relationships of PSA to prostate volume, PSA to outcomes, & prostate volume to outcomes. • * Collected & analyzed competitive product
information at AUA (alpha blockers, Dutasteride, herbal products) Training of Urology Sales Force • High quality training lectures given to sales force trainees—top rating given by sales trainees • Trained sales force on key promotional piece “A Profile of Proscar” • Pro-actively wrote three
SUPPORT MARKETING AND
Medical Background texts & tests for PSA launch • Reviewed/edited & assisted in writing sales bulletins (e.g., PREDICT study, Dr. Pitt’s negative editorial in J Urol)
Medical Review & Assistance in Development of Promotional Materials • Participation in M/L boards • Researched & provided medical literature to support promotional efforts • Assistance to TBG & legal in drafting
SALES TEAMS WITH
promotional materials by providing product, medical & urological expertise (e.g., “A Profile of Proscar”, “BPH: A Primary Care Perspective”, review of all key studies ‘92-’00) • * M/L board liaison with MRL
MEDICAL & SCIENTIFIC
Issue Research & Analysis Responded to 1
00% of Issues • Ongoing monitoring of the finasteride & competitive disease literature & the Internet, for US MEDSA, TBG, WHHM & MRL (e.g., quarterly alfusozin searches for
MEDSA & TBG; identification of AUA abstr acts of interest for the Merck AUA meeting book) • *Ongoing extensive literature & database research & analysis (e.g., intraprostatic DHT levels; Lower Urinary Tract Symptoms)
INFORMATION
• *Participation in USHH-MRL-WHHM Prostate Cancer Product Development Team
Work With Marketing to Develop & Execute a Plan to Train Sales Force • Developed MEDSA Dutasteride plan • *Created outline, provided source materials and reviewed WHHM MB (outline and source material being
incorporated into promotional slide set) • Assisted TBG in planning & implementing promotional strategy to pre-empt Glaxo • *Created & gave training lectures to both HSA’s & to USHH team
Issue Research and Analysis • Performed 100% of liter
ature searches & analyses • *Acti H
ve participants in the USHH team & USHH/WHHM/MRL Counterstrategy Task Force to plan & implement strategy • *Assisted TBG in analyzing
competitive data, planning & implementing counter- & promotional-strategy to pre-empt Glaxo DUTASTERIDE
Search and Monitor Product and Competitive Literature • Quarterly Literature Search on Dutasteride • Performed quarterly surveillance literature searches for the task force (TBG, MRL, WHHM)
Search and Monitor Literatur
PREPARE FOR THE M3 ANTAGONIST†
e, Databases, and Internet • Begin to Develop Center of Expertise in Neurourology • Provided literature for new product marketing, market research, etc. • Collected voiding dysfunction
& incontinence related material at AUA •
Identified texts for library • Assisted in early strategic planning
– PENDING PHASE IIB TRIAL RESULTS
†Did not continue into Phase III
Henry Rodrique, APA; Joanne Palmisano, Lee Halper, CDP; Leonard Silverstein (chair),
Kathleen Peeples-Lamirande, Medical Services; Tom Abbott, ORM; Fran Kaiser, RMD
Designed and Produced by the DTP Group/InfoManagement Team/Medical Services

Source: http://helenmitchell.com/images/pfolio/PROSCAR_POSTER.pdf